We also observed that α-bisabolol was active against primary BCR-ABL+ acute lymphoblastic leukemias (ALL), including cases harboring mutations which conferred resistance to imatinib [13]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.